

October 5, 2017

Torii Pharmaceutical Co., Ltd.

Torii announces Postponement of Price Listing on the NHI Reimbursement List for
“CEDARCURE[®] Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy
Tablet for Japanese Cedar Pollinosis

Torii Pharmaceutical Co., Ltd. (TSE:4551) announced today that the price listing of “CEDARCURE[®] Japanese Cedar Pollen Sublingual Tablets” (Development code: TO-206, “CEDARCURE” hereinafter), an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis, on the National Health Insurance reimbursement list in November will be postponed. CEDARCURE was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) on September 27, 2017. Torii has been preparing to have the price of CEDARCURE listed in November and to launch it promptly after the price listing. Torii will continue its effort for the next price listing, and expects that expanded therapeutic option can contribute to the treatment of Japanese cedar pollinosis with CEDARCURE.

This announcement does not lead Torii to a change of its financial outlook for the fiscal year ending December 2017.

<About CEDARCURE >

CEDARCURE is the first regulatory approved sublingual tablet available for adult and pediatric patients in Japan. CEDARCURE has characteristics such as higher dosage and improved convenience of use with storage at room temperature compared to “CEDARTOLEN[®] SUBLINGUAL DROP - Japanese Cedar Pollen”, an Allergen Immunotherapy Drop for Japanese Cedar Pollinosis, launched in October 2014.

Positive results were obtained from the Phase II/III clinical study of CEDARCURE in Japanese patients with Japanese cedar pollinosis (5-64 years), proving that sublingually administered CEDARCURE reduced symptoms of the Japanese cedar pollinosis, providing statistically significant improvement in “Total Combined Rhinitis Score (TCRS)” compared to placebo as shown in the study. Furthermore, no specific finding was observed in safety.